Pandora’s Box of AML: How TP53 Mutations Defy Therapy and Hint at New Hope

<i>TP53</i> mutations are among the worst prognostic factors in acute myeloid leukemia (AML), with affected patients facing relapse-free survival of just five-to-six months compared to <i>TP53</i> wild-type patients. A major barrier to improving outcomes lies in the dearth of effective therapies, as <i>TP53</i> mutant patients remain refractory to conventional cytotoxic chemotherapies, targeted therapies, and even allogeneic stem cell transplantation. In this review, we first summarize current clinical strategies and the major setbacks of p53 activators, MDM2/X regulators, and immunotherapy, highlighting the disconnect between promising pre-clinical studies and limited durable clinical responses. We next discuss the mechanisms of therapy resistance in <i>TP53</i> mutant AML, with specific emphasis on dysfunction in the mitochondrial apoptotic pathway and clonal evolution of <i>TP53</i> mutant hematopoietic stem cells. We then outline a roadmap for developing tailored therapies that may finally redefine prognosis for this high-risk patient population, including apoptotic activators, cell-cycle modulators, and immune- and metabolic-based therapies. We lastly call attention to new biomarker-driven approaches that can improve patient stratification and optimize identification of responders. By connecting mechanistic understanding with translational insights, this review underscores both the formidable challenges and the emerging opportunities in <i>TP53</i> mutant AML.